fair enough
interestingly no less an authority than josh berger himself posted a slide including polymerase inhibitors with telaprivir as the future of HCV therapy, so assuming nm-283 makes it through, regardless of efficacy compared with proteas inhibitors, one can say none other than the CEO/chairman of vertex also disagrees with these analysts (although it should be noted the role of a polynmerase was downplayed in his presentation as years away and as an adjuvant to the central role of telaprevir in future HCV therapy..all totally understandable assertions given where he sits as the head of vertex)
Market Data 
Markets 
AI
